U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT06836518) titled 'Sialic Acid in Hepatocellular Carcinoma' on Feb. 14.
Brief Summary: Hepatocellular carcinoma (HCC) accounts for approximately 90% of the cases of liver cancer and is associated with high morbidity and mortality.
The increased sialic acids(SAs) in tumor cells are mainly caused by the special metabolic flux and aberrant expression of sialyltransferases/sialidases, The high sensitivity of sialic acids in or plasma as a tumor marker has been reported in various cancerous conditions the level of sialic acid(SA) activity was found to offer highly specific and sensitive tumor biomarker for diagnosis and follow up of HCC post-therapy.
Stu...